Insight

Andrew W Hahn: How effective and tolerable is Belzutifan in treating Sporadic Metastatic Clear Cell Renal Cell Carcinoma

Andy Hahn/X

Oct 7, 2024, 07:05

Andrew W Hahn: How effective and tolerable is Belzutifan in treating Sporadic Metastatic Clear Cell Renal Cell Carcinoma

Andrew W Hahn, Genitourinary Medical Oncologist, MD Anderson Cancer Center, shared a post on X:

“ Check out our single-center, real-world experience with belzutifan in 22 patients with metastatic Clear Cell Renal Cell Carcinoma who were treated prior to the FDA approval. Led by our outstanding pharmacist, Emily Wang.

Belzutifan had meaningful activity in this heavily pre-treated cohort with ORR of 36.4%, median PFS of 8.5 months, and median OS of 14.7 months. We provide a detailed summary of the responders to belzutifan and our experience managing AEs of hypoxia and anemia.“

Belzutifan Efficacy and Tolerability in Patients with Sporadic Metastatic Clear Cell Renal Cell Carcinoma

Authors: Emily Wang, Eric S Rupe, Sagar S Mukhida, Andrew C Johns, Matthew T Campbell, Amishi Y Shah, Amado J Zurita, Jianjun Gao, Sangeeta Goswami, Eric Jonasch, Pavlos Msaouel, Nizar M Tannir and Andrew W Hahn.

Source: Andy Hahn/X

Amado J Zurita Amishi Y Shah Andrew C Johns Andrew W Hahn Andy Hahn belzutifan cancer cancer awareness cancer care Emily Wang Eric Jonasch Eric S Rupe fight against cancer Global fight against cancer Jianjun Gao Matthew T Campbell Nizar M. Tannir OncoDaily Oncology Pavlos Msaouel RENAL CARCINOMA Sagar S Mukhida Sangeeta Goswami

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Special Coverage